Get the Stockscreener App
83.01
0.41%
0.34
After Hours:
82.50
-0.51
-0.61%
Zimmer Biomet Holdings Inc stock is traded at $83.01, with a volume of 1.61M.
It is up +0.41% in the last 24 hours and down -8.67% over the past month.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
See More
Previous Close:
$82.67
Open:
$83.08
24h Volume:
1.61M
Relative Volume:
0.69
Market Cap:
$16.06B
Revenue:
$8.41B
Net Income/Loss:
$760.80M
P/E Ratio:
21.55
EPS:
3.8513
Net Cash Flow:
$1.05B
1W Performance:
+0.25%
1M Performance:
-8.67%
6M Performance:
-5.19%
1Y Performance:
-8.26%
1-Day Range:
$82.14
$83.68
1-Week Range:
$79.83
$84.09
52-Week Range:
$79.83
$108.29
Zimmer Biomet Holdings Inc Stock (ZBH) Company Profile
Name
Zimmer Biomet Holdings Inc
Sector
Industry
Phone
(574) 267-6131
Address
345 EAST MAIN STREET, WARSAW, IN
Compare ZBH vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZBH
Zimmer Biomet Holdings Inc
|
83.01 | 15.99B | 8.41B | 760.80M | 1.05B | 3.8513 |
ABT
Abbott Laboratories
|
87.17 | 152.48B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
295.25 | 111.40B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
77.79 | 100.53B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
55.98 | 84.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.91 | 48.04B | 6.30B | 1.07B | 1.34B | 1.8406 |
Zimmer Biomet Holdings Inc Stock (ZBH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-23-26 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-20-26 | Initiated | William Blair | Mkt Perform |
| Jan-09-26 | Downgrade | Goldman | Neutral → Sell |
| Jan-06-26 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-05-26 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-06-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-18-25 | Initiated | Rothschild & Co Redburn | Buy |
| Jul-15-25 | Upgrade | Roth Capital | Neutral → Buy |
| Dec-17-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-10-24 | Initiated | Wolfe Research | Peer Perform |
| Jul-01-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-30-24 | Initiated | Goldman | Neutral |
| May-21-24 | Upgrade | Argus | Hold → Buy |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-20-23 | Initiated | ROTH MKM | Neutral |
| Aug-28-23 | Upgrade | BTIG Research | Neutral → Buy |
| May-03-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Apr-11-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Upgrade | Jefferies | Underperform → Hold |
| Mar-29-23 | Initiated | UBS | Sell |
| Mar-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-09-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-03-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-23-22 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-18-22 | Initiated | Barclays | Underweight |
| Oct-12-22 | Initiated | Jefferies | Underperform |
| May-27-22 | Downgrade | Needham | Buy → Hold |
| Apr-13-22 | Downgrade | Truist | Buy → Hold |
| Apr-01-22 | Downgrade | Citigroup | Buy → Neutral |
| Mar-02-22 | Resumed | BofA Securities | Underperform |
| Mar-02-22 | Downgrade | Loop Capital | Buy → Hold |
| Feb-08-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-08-22 | Reiterated | Citigroup | Buy |
| Feb-08-22 | Reiterated | Deutsche Bank | Hold |
| Feb-08-22 | Reiterated | JMP Securities | Mkt Outperform |
| Feb-08-22 | Reiterated | JP Morgan | Neutral |
| Feb-08-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-08-22 | Reiterated | Stifel | Buy |
| Feb-08-22 | Reiterated | Truist | Buy |
| Feb-08-22 | Reiterated | UBS | Neutral |
| Feb-08-22 | Reiterated | Wells Fargo | Underweight |
| Feb-02-22 | Downgrade | UBS | Buy → Neutral |
| Jan-19-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Jan-10-22 | Downgrade | Mizuho | Buy → Neutral |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-04-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-09-21 | Downgrade | Needham | Strong Buy → Buy |
| Dec-07-21 | Initiated | Loop Capital | Buy |
| Nov-23-21 | Downgrade | Argus | Buy → Hold |
| Sep-14-21 | Resumed | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-09-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jan-04-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-18-20 | Reiterated | Needham | Strong Buy |
| Oct-20-20 | Initiated | Northland Capital | Market Perform |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Aug-05-20 | Reiterated | Needham | Strong Buy |
| Apr-28-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-09-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-07-20 | Reiterated | Needham | Strong Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Buy |
| Jan-08-20 | Initiated | SunTrust | Buy |
| Jan-07-20 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jan-07-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-04-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-07-19 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-18-19 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-12-19 | Upgrade | Argus | Hold → Buy |
| Jul-30-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-11-19 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Apr-24-19 | Upgrade | Needham | Buy → Strong Buy |
View All
Zimmer Biomet Holdings Inc Stock (ZBH) Latest News
Zimmer Biomet (ZBH) CAO awarded 9,232 RSUs vesting over three years - Stock Titan
How Zimmer Biomet Holdings Inc. (ZBH) Affects Rotational Strategy Timing - Stock Traders Daily
Why Zimmer Biomet (ZBH) is a Top Growth Stock for the Long-Term - Yahoo Finance
Zimmer Biomet (ZBH) Is Down 9.2% After Strong Q1, CFO Exit And Ongoing Buybacks – Has The Bull Case Changed? - Sahm
Robertson Stephens Wealth Management LLC Buys Shares of 12,539 Zimmer Biomet Holdings, Inc. $ZBH - MarketBeat
Zimmer Biomet Announces Chief Financial Officer Transition - Building Indiana Business
BofA Securities Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Maintains Target Price $100 - Moomoo
Zimmer Biomet Holdings 1Q 2026: Revenue $2.09B, EPS $1.22— 10-Q Summary - TradingView
Zimmer Biomet (NYSE: ZBH) posts Q1 2026 growth and updates 2026 view - Stock Titan
Zimmer Biomet Ordered to Defend Fraud Claim in Device Deal Case - Bloomberg Law News
Zimmer Biomet Announces Webcast and Conference Call of First Quarter 2026 Financial Results - Quantisnow
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock - Yahoo Finance
Results: Zimmer Biomet Holdings, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - simplywall.st
Zimmer Biomet Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Vanguard holds 7.54% of Zimmer Biomet (ZBH) via Schedule 13G filing - Stock Titan
Zimmer Biomet falls after CEO exit, unchanged growth outlook - MSN
Zimmer Biomet Stock (US98956P1021): Q3 2025 Earnings Beat Expectations with 5.2% Revenue Growth - AD HOC NEWS
A Look At Zimmer Biomet (ZBH) Valuation After CFO Exit And Solid Quarterly Results - Yahoo Finance
A Quick Look at Today's Ratings for Zimmer Biomet Holdings(ZBH.US), With a Forecast Between $83 to $105 - Moomoo
Zimmer Biomet Holdings (ZBH) Receives a Hold from Truist Financial - The Globe and Mail
RBC Capital Sticks to Their Buy Rating for Zimmer Biomet Holdings (ZBH) - The Globe and Mail
Vanguard Group Inc. Buys 192,517 Shares of Zimmer Biomet Holdings, Inc. $ZBH - MarketBeat
Zimmer Biomet Holdings Hits New 52-Week Low at $81.36 - Markets Mojo
Zimmer Biomet Buzz Grows Across NYSE Composite Trend - Kalkine Media
Zimmer Biomet Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Zimmer Biomet (NYSE:ZBH) Given New $95.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Zimmer Biomet Q1 2026 earnings preview - MSN
Zimmer Biomet Supported by Sales Force Improvements, 2026 Upside Potential, RBC Says - marketscreener.com
Zimmer Biomet (NYSE:ZBH) Price Target Cut to $105.00 by Analysts at Citizens Jmp - MarketBeat
Zimmer Biomet CFO Suketu Upadhyay to depart - MSN
Wells Fargo & Company Lowers Zimmer Biomet (NYSE:ZBH) Price Target to $90.00 - MarketBeat
Zimmer Biomet (NYSE:ZBH) Price Target Lowered to $105.00 at Stifel Nicolaus - MarketBeat
Zimmer Biomet's (ZBH) Hold Rating Reaffirmed at Truist Financial - MarketBeat
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Q1 2026 Earnings Call Transcript - Insider Monkey
JPMorgan Adjusts Price Target on Zimmer Biomet Holdings to $95 From $100, Maintains Neutral Rating - marketscreener.com
Citigroup Adjusts Price Target on Zimmer Biomet to $95 From $98, Maintains Neutral Rating - marketscreener.com
Baird Adjusts Price Target on Zimmer Biomet to $92 From $100, Maintains Neutral Rating - marketscreener.com
Zimmer Biomet net sales up 9.3% to USD 2.087B in Q1 2026 - Medical Buyer
Barclays Adjusts Price Target on Zimmer Biomet to $94 From $100, Maintains Underweight Rating - marketscreener.com
Goldman Sachs Adjusts Price Target on Zimmer Biomet to $86 From $89, Maintains Sell Rating - marketscreener.com
Wells Fargo Adjusts Price Target on Zimmer Biomet to $90 From $98, Maintains Equalweight Rating - marketscreener.com
Stifel Adjusts Price Target on Zimmer Biomet to $105 From $110, Maintains Buy Rating - marketscreener.com
Citizens cuts Zimmer Biomet stock price target on mixed results By Investing.com - Investing.com South Africa
Zimmer Biomet (NYSE:ZBH) Hits New 12-Month LowShould You Sell? - MarketBeat
Citizens cuts Zimmer Biomet stock price target on mixed results - Investing.com
Cwm LLC Reduces Stock Position in Zimmer Biomet Holdings, Inc. $ZBH - MarketBeat
Zimmer Biomet Holdings Inc (ZBH) Q1 2026 Earnings Call Highlights: Strong Start with 9.3% Revenue Growth - GuruFocus
Zimmer Biomet Q1 Earnings Call Highlights - MarketBeat
Zimmer Biomet (ZBH) Proxy filing Summary - Quartr
Zimmer Biomet (ZBH) Plunges to 13-Year Low on Finance Chief Resignation - Yahoo Finance
Stifel cuts Zimmer Biomet stock price target on mixed quarter By Investing.com - Investing.com India
Zimmer Biomet Holdings Inc Stock (ZBH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):